FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

FORCE Blog

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 7,222 other subscribers

Archives

Posts Tagged ‘BRCA 1’

June 17, 2018

Solving for Y: Reaching Men About Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, Prostate And Related Cancers (HBOC)

by Sue Friedman Half of all people with an inherited BRCA, ATM, CHEK2, PALB2 or other mutation associated with HBOC are men. Nevertheless, the majority of awareness, research, and resources have focused on genetic testing in women. A recent article in JAMA highlights this disparity in BRCA testing between men and women. Emerging information on … + read more

May 21, 2018

FORCE Earns 4-Star Rating on Charity Navigator

By Karen Kramer, Senior Vice President of Marketing We have some exciting news to share! Non-profit evaluator Charity Navigator has awarded FORCE our first 4-star rating. This is their highest possible rating and indicates that we exceed industry standards in a financially responsible way. Charity Navigator bases its ratings on non-profits’ financial health and commitment … + read more

April 27, 2018

The Lights of May

Special note: In honor of Mother’s Day 2018, we’re recycling this post that was originally published in 2012. This inspirational post is as relevant as when first written 6 years ago.  by Sue Friedman We were late.  The last hint of twilight faded and although we were close to home, I was nervous.  It was … + read more

March 19, 2018

Where’s FORCE? Early 2018

by Lisa Schlager Throughout the year, FORCE staff and volunteers participate in a variety of conferences, workshops, steering committee meetings, and more on behalf of the hereditary cancer community. This “Where’s FORCE” feature covers the early part of 2018. January January marked the start of the New Year, and renewed focus on issues that impact … + read more

February 28, 2018

Five Year Ovarian Cancerversary

by Cindy McKinnon Deurloo Five years ago I heard the only words a cancer patient wants to hear “you’re cancer free and in remission.” After the painful surgery (radical hysterectomy), surgical menopause, 6 rounds of aggressive chemotherapy that made me very ill, multiple blood transfusions, hospital stays and scars, I made it!! How blessed am I to … + read more

November 20, 2017

Why is Mommy Having Surgery, She Looks Ok to Me

By: Heather Barnard I wish the circumstances were different, but the fact of the matter is, I come from a long line of women with breast cancer. My mother, grandmother and great-grandmother all suffered from it. While my grandmother was able to beat the odds way back in 1966, my own mother was not; she passed … + read more

May 18, 2017

Science and the Media: Help vs. Hype

by Piri Welcsh, PhD and Sue Friedman, DVM When making medical decisions, getting information right is more important than getting it fast. This is especially true for our community, when results of a genetic test or a breast biopsy can add a sense of urgency to medical decision-making. But finding factual data or input—help, not … + read more

May 11, 2017

Fueling Patient-Focused Health Care

by Melanie Nix I know a woman who has hereditary breast and ovarian cancer (HBOC) syndrome. She is a triple negative breast cancer survivor. She has a BRCA1 gene mutation and is the fifth generation in her family to have breast cancer. She lost her youngest aunt to ovarian cancer after multiple battles with both … + read more

March 28, 2017

SOLO3: A Clinical Trial Comparing the PARP Inhibitor, Olaparib to Standard Chemotherapy for Platinum-Sensitive Relapsed Ovarian Cancer

by Jordan Dietrich  SOLO3 SOLO3 is an exciting phase III ovarian cancer clinical trial that studies the effectiveness and safety of the PARP inhibitor Olaparib (Lynparza) compared to single-agent standard chemotherapy in women with platinum-sensitive relapsed ovarian cancer with germline BRCA1/2 mutations. The trial is designed to confirm the benefit of Olaparib in this subset of … + read more

February 23, 2017

Post-Reconstruction Thoughts on “Going Flat”

Note: This is part 1 of a 3-part series related to our recent XRAYS review on Roni Caryn Rabin’s New York Times piece “‘Going Flat’ After Breast Cancer.” by Robin Karlin Roni Caryn Rabin’s New York Times piece, “‘Going Flat’ After Breast Cancer,” brings much-needed awareness to the option of skipping reconstruction after mastectomies for breast … + read more

February 15, 2017

Guest Blog: Join FORCEs at our 2017 HBOC Conference!

by guest blogger, Jane E. Herman When I boarded the flight for my first trip to Orlando in June 2011, my goal was not to hug Mickey Mouse or visit Cinderella’s Castle. Rather, my destination was the sixth annual Joining FORCEs Conference. Not knowing anyone who would be in attendance, I was – not unexpectedly … + read more

January 31, 2017

MEDIOLA: A Clinical Trial Combining a PARP Inhibitor with an Immunotherapy Drug

By Ding Wang, MD and Catherine Jenovai Immune system and cancer Every day our bodies are exposed to various injuries that may damage our cells. The damaged cells with certain types of genetic defects are tagged as abnormal and removed by our immune system. If something goes wrong and the cells are not removed by … + read more

January 26, 2017

Flawed Research and Reporting on the “Angelina Effect” Could Threaten Access to HBOC Care

by Lisa Schlager, Lisa Rezende, PhD and Sue Friedman “Angeline Effect” Angelina Jolie’s May 2013 New York Times editorial “My Medical Choice,” which detailed her decision to have a double mastectomy because she carries a BRCA1 mutation brought unprecedented attention to hereditary cancer and BRCA genetic testing. This “Angelina Effect” created an avalanche of public … + read more

January 12, 2017

Update on Hormone Therapy for Previvors

by Alexandria Groves and Lisa Rezende, PhD National guidelines recommend that women with mutations in BRCA have risk-reducing removal of their ovaries and tubes, (also known as salpingo-oophorectomy or RRSO) either between the ages of 35-40 or after they are done having children. RRSO greatly reduces the risk of ovarian, fallopian tube, and peritoneal cancer, … + read more

January 5, 2017

FORCE Collaborates on Genetics Toolkit for Health Care Providers to Help Improve Patient Care

by Alexandria Groves In October The Society of Gynecologic Oncology (SGO) announced the release of the SGO Genetics Toolkit to provide critical and important information to health professionals, patients and their families, and anyone who wants a deeper understanding of gynecologic cancers and genetics. The Toolkit is the result of a collaboration between experts from … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered